<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Medipal Holdings Corporation — News on 6ix</title>
    <link>https://6ix.com/company/medipal-holdings-corporation</link>
    <description>Latest news and press releases for Medipal Holdings Corporation on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 29 Sep 2025 16:33:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/medipal-holdings-corporation" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d63472beedb30cb6fcb1c4.webp</url>
      <title>Medipal Holdings Corporation</title>
      <link>https://6ix.com/company/medipal-holdings-corporation</link>
    </image>
    <item>
      <title>Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan</title>
      <link>https://6ix.com/company/medipal-holdings-corporation/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-ministry-of-health-labour-and-welfare-of-japan-1</link>
      <guid isPermaLink="true">https://6ix.com/company/medipal-holdings-corporation/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-ministry-of-health-labour-and-welfare-of-japan-1</guid>
      <pubDate>Mon, 29 Sep 2025 16:33:00 GMT</pubDate>
      <description>TOKYO &amp; HYOGO, Japan, September 29, 2025--JCR and MEDIPAL announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446 for MPS IIIB.</description>
    </item>
    <item>
      <title>MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis</title>
      <link>https://6ix.com/company/medipal-holdings-corporation/news/medipal-holdings-and-jcr-pharmaceuticals-sign-global-licensing-and-japan-co-development-agreement-for-jr-479-a-novel-therapy-for-gm2-gangliosidosis-1</link>
      <guid isPermaLink="true">https://6ix.com/company/medipal-holdings-corporation/news/medipal-holdings-and-jcr-pharmaceuticals-sign-global-licensing-and-japan-co-development-agreement-for-jr-479-a-novel-therapy-for-gm2-gangliosidosis-1</guid>
      <pubDate>Tue, 02 Sep 2025 16:31:00 GMT</pubDate>
      <description>TOKYO &amp; HYOGO, Japan, September 02, 2025--JCR and MEDIPAL announced an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479.</description>
    </item>
    <item>
      <title>Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)</title>
      <link>https://6ix.com/company/medipal-holdings-corporation/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-european-commission-ec-1</link>
      <guid isPermaLink="true">https://6ix.com/company/medipal-holdings-corporation/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-european-commission-ec-1</guid>
      <pubDate>Tue, 24 Jun 2025 16:38:00 GMT</pubDate>
      <description>TOKYO &amp; HYOGO, Japan, June 24, 2025--JCR and MEDIPAL announced that the EC has granted ODD to JR-446, an investigational drug for the treatment of mucopolysaccharidosis type IIIB.</description>
    </item>
    <item>
      <title>Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA</title>
      <link>https://6ix.com/company/medipal-holdings-corporation/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-the-us-fda-1</link>
      <guid isPermaLink="true">https://6ix.com/company/medipal-holdings-corporation/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-the-us-fda-1</guid>
      <pubDate>Wed, 07 May 2025 15:31:00 GMT</pubDate>
      <description>TOKYO &amp; HYOGO, Japan, May 07, 2025--MEDIPAL and JCR announced that the U.S. FDA granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of MPS IIIB.</description>
    </item>
  </channel>
</rss>